Gestagens in the management of prostatic carcinoma
- PMID: 6100181
- DOI: 10.1007/BF02081869
Gestagens in the management of prostatic carcinoma
Abstract
Two different hormonal gestagens, cyproterone acetate and norethisterone, were studied in prostatic carcinoma, for the greatest part in advanced cases. Cyproterone acetate was administered to 80, norethisterone to 38 unselected patients. The period of study extended over 2 years or more. The mechanism of action of gestagens and the role of the hormone receptors are discussed. The significance of serial measurements of plasma testosterone by providing a monitor of hormonal therapy is emphasized. The relevant literature is reviewed. The value of gestagens as an alternative to the traditional hormone therapy of prostatic carcinoma is pointed out.
Similar articles
-
[Therapy of virginal prostatic cancer with cyproterone acetate].Z Urol Nephrol. 1985 Apr;78(4):181-7. Z Urol Nephrol. 1985. PMID: 3160180 German.
-
The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.Scand J Urol Nephrol. 1982;16(1):31-6. doi: 10.3109/00365598209179637. Scand J Urol Nephrol. 1982. PMID: 6211762
-
The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.Prostate Suppl. 1992;4:91-5. doi: 10.1002/pros.2990210514. Prostate Suppl. 1992. PMID: 1533452 Review.
-
The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma.J Urol. 1988 Dec;140(6):1460-5. doi: 10.1016/s0022-5347(17)42073-8. J Urol. 1988. PMID: 2973529
-
Cyproterone acetate as monotherapy in prospective randomized trials.Prog Clin Biol Res. 1990;359:85-91; discussion 105-7. Prog Clin Biol Res. 1990. PMID: 2149459 Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Medical